Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCI-NRG ALK Protocol trial: what clinicians have said so far
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
- NCT03737994 ↗
- Terminated
- National Cancer Institute (NCI)
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCI-NRG ALK Protocol (alectinib; brigatinib; lorlatinib in previously treated ALK-positive stage IV non-squamous NSCLC) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCI-NRG ALK Protocol so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
- Phase
- Phase 2
- Status
- Terminated
- Conditions
- Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
- Interventions
- Alectinib; Brigatinib; Carboplatin; Ceritinib; Cisplatin; Crizotinib; Ensartinib; Lorlatinib; Pemetrexed
- Arms
- ALK L1198F mutation (alone or combination with ALK inhibitor) · Experimental
- C1156Y · Experimental
- Compound mutation · Experimental
- F1174 · Experimental
- G1202 (including G1202del and G1202R) · Experimental
- I1171 · Experimental
- L1196 (including L1196M) · Experimental
- MET amplification · Experimental
- No ALK-resistance mutations · Experimental
- V1180 · Experimental
- Enrollment
- 10
- Primary outcomes
- Objective Response Rate (ORR), Per Investigator Assessment Using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Criteria
- Sponsor
- National Cancer Institute (NCI) with NRG Oncology
- Start
- Jul 25, 2019
- Primary completion
- Jul 21, 2021
- Results posted
- Yes
- Registry record
- NCT03737994 · updated Apr 23, 2026